Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases
Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally.
Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Wednesday. Stay informed about the latest market trends.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
Stocks continued to be under pressure on concerns over tariffs and growing inflation concerns, but history shows that corrections can set up opportunities
Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Let's delve into the developments on the US markets in the middle of the day on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Tuesday. Discover the gap up and gap down stocks in the S&P500 index.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN).
